美国精准肿瘤学领域领军企业Guardant Health Inc.宣布，其多癌种早期检测(MCD)技术Shield已启动美国国家癌症研究所(NCI)先锋研究的患者招募。该技术目前正接受美国食品药品监督管理局(FDA)审查，作为NCI试验器械豁免(IDE)计划的重要组成部分。
这项具有里程碑意义的癌症检测研究计划招募24,000名参与者，旨在评估多癌检测技术在后续临床试验中的应用可行性。由癌症筛查研究网络主导的先锋研究，将重点验证此类检测技术对早期癌症发现的效能，及其在降低癌症死亡率方面的临床价值。
研究采用的前瞻性队列设计将系统评估多癌检测技术对结直肠癌、胰腺癌等致命性癌症的筛查效果。通过血液样本分析循环肿瘤DNA(ctDNA)的表观遗传特征，Shield技术可同时筛查多种癌症类型，为癌症早筛领域带来突破性进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.